Jeremy Cherfas (Eat This Podcast)Our Daily Bread was a contribution to the Dog Days of Podcasting, with an episode every day through the month of August 2018.
As the senator prepares to leave office, she sat down with us to talk about her defeat in the midterm elections and the path forward for the Democratic Party.
Create your own podcast: find links to audio files on the Web; huffduff the links (add them to your podcast); subscribe to podcasts of other found sounds.
While the site does a pretty good job of describing itself and the fact that it has a wonderful bookmarklet, I’ll also point out that Ryan Barrett has a video bookmarklet for it that “extracts the audio from videos on YouTube, Vimeo, and many more sites and sends it to Huffduffer.”
If you’re a podcastaphile, it’s a de rigueur tool. While I publish a listen feed on my website, you can also follow me on Huffduffer if you wish. If you’re using it, do let me know so I can add you to my “collective”. This will let me find the great audio you’re discovering.
I should tell Jeremy Keith more often I love that he runs this little service: Thanks for making the world so much brighter!
If you need almost five hours of all the extant Hallelujah covers on Spotify to soothe your soul (for any reason), please feel free to save yourself the time of building it and enjoy my playlist. If you’re aware of any missing covers (that exist on Spotify), please let me know and I’m happy to add them to the collection.
Keep your chin up!
Now I’ve heard there was a secret chord
That David played, and it pleased the Lord
But you don’t really care for music, do you?
It goes like this
The fourth, the fifth
The minor fall, the major lift
The baffled king composing HallelujahHallelujah, Hallelujah
Hallelujah, Hallelujah
Analysis of phase 1 and 2 trials testing the safety of spinal cord transplantation of human stem cells in patients with amyotrophic lateral sclerosis (ALS) with escalating doses and expansion of the trial to multiple clinical centers.
CNN also has a general interest article talking about some of the results.
Links to some earlier articles:
Transplantation of spinal cord–derived neural stem cells for ALS
Analysis of phase 1 and 2 trials
Authors: Jonathan D. Glass, MD; Vicki S. Hertzberg, PhD; Nicholas M. Boulis, MD; Jonathan Riley, MD; Thais Federici, PhD; Meraida Polak, RN; Jane Bordeau, RN; Christina Fournier, MD; Karl Johe, PhD; Tom Hazel, PhD; Merit Cudkowicz, MD; Nazem Atassi, MD; Lawrence F. Borges, MD; Seward B. Rutkove, MD; Jayna Duell, RN; Parag G. Patil, MD; Stephen A. Goutman, MD; Eva L. Feldman, MD, PhD
ABSTRACT
Objective: To test the safety of spinal cord transplantation of human stem cells in patients with amyotrophic lateral sclerosis (ALS) with escalating doses and expansion of the trial to multiple clinical centers.
Methods: This open-label trial included 15 participants at 3 academic centers divided into 5 treatment groups receiving increasing doses of stem cells by increasing numbers of cells/injection and increasing numbers of injections. All participants received bilateral injections into the cervical spinal cord (C3-C5). The final group received injections into both the lumbar (L2-L4) and cervical cord through 2 separate surgical procedures. Participants were assessed for adverse events and progression of disease, as measured by the ALS Functional Rating Scale–Revised, forced vital capacity, and quantitative measures of strength. Statistical analysis focused on the slopes of decline of these phase 2 trial participants alone or in combination with the phase 1 participants (previously reported), comparing these groups to 3 separate historical control groups.
Results: Adverse events were mostly related to transient pain associated with surgery and to side effects of immunosuppressant medications. There was one incident of acute postoperative deterioration in neurologic function and another incident of a central pain syndrome. We could not discern differences in surgical outcomes between surgeons. Comparisons of the slopes of decline with the 3 separate historical control groups showed no differences in mean rates of progression.
Conclusions: Intraspinal transplantation of human spinal cord–derived neural stem cells can be safely accomplished at high doses, including successive lumbar and cervical procedures. The procedure can be expanded safely to multiple surgical centers.
Classification of evidence: This study provides Class IV evidence that for patients with ALS, spinal cord transplantation of human stem cells can be safely accomplished and does not accelerate the progression of the disease. This study lacks the precision to exclude important benefit or safety issues.
Source: Transplantation of spinal cord–derived neural stem cells for ALS
